[A19-17] Encorafenib (melanoma) - Addendum to Commission A18-61
Last updated 22.03.2019
Project no.:
A19-17
Commission:
Commission awarded on 12.03.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
Added benefit still not proven for pretreated or treatment-naive patients after analysis of further data on adverse events on the adjusted indirect comparison of the studies COLUMBUS and coBRIM
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-61 | Encorafenib (melanoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.